A Phase I/II Study of AZD0466 as Monotherapy or in Combination with Anticancer Agents in Advanced Non-Hodgkin Lymphoma

Study identifier:D8242C00001

ClinicalTrials.gov identifier:NCT05205161

EudraCT identifier:2021-003410-39

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Modular Phase I/II, Open-label, Dose Escalation and Expansion, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0466 as Monotherapy or in Combination with Anticancer Agents in Patients with Advanced Non-Hodgkin Lymphoma.

Medical condition

Non-Hodgkin Lymphoma

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD0466

Sex

All

Actual Enrollment

7

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 05 Jul 2022
Primary Completion Date: 17 Aug 2023
Study Completion Date: 17 Aug 2023

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria